This study aims to assess the safety, tolerability, efficacy and pharmacokinetics of Ig
NextGen 16% in people with antibody deficiency currently being treated with IntragamP. Ig
NextGen 16% is a liquid immunoglobulin (antibody) preparation manufactured using
predominately chromatographic techniques. Eligible patients will switch from monthly
intravenous IntragamP therapy to weekly subcutaneous Ig NextGen 16% treatment. Initial
hospital training will be required for subcutaneous administration and then the patient will
perform the infusion in their own home, returning once a month for a supervised infusion.
Patients will be monitored on the study for up to 10 months to assess blood IgG levels and
rate of serious bacterial infections.